For example, the FAP-targeting monoclonal antibody sibrotuzumab and the FAP-inhibiting small-molecule inhibitor talabostat did not show any objective response in phase II trials for metastatic colorectal cancer [47, 48]. Here, FAP is linked to metastatic colorectal cancer.